Prostamax (Lys-Glu-Asp-Pro) is a synthetic tetrapeptide from Vladimir Khavinson’s bioregulatory peptide program, classified as a prostate bioregulator. Preclinical studies have examined its effects on prostate tissue function. Research is published primarily in Russian-language journals with minimal Western peer-reviewed replication.

📖 Read the full Prostamax research overview →

Evidence Tier: Tier 4 — Preclinical Only · Peptidings Verdict: Thin Ice